According to a recent LinkedIn post from Xeltis, the company’s clinical team visited the dialysis clinic at Zemun Hospital in Belgrade, Serbia, which is participating in the next phase of its aXess clinical trials. The post highlights that the Zemun site, led by Prof. Tamara Jemcov, has already implanted four patients with Xeltis’s novel ETR hemodialysis conduit.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests that all four patients are reported as doing well and are successfully undergoing dialysis using the aXess conduit, following a review of outcomes by Xeltis specialists. For investors, these early clinical signals may indicate progress in validating the technology, which could support future regulatory pathways, broader EU site adoption, and, over time, potential commercial opportunities in the vascular access segment.
The involvement of a center led by the President of the Vascular Access Society may enhance the perceived credibility and visibility of the aXess program within the nephrology community. If subsequent trial phases continue to deliver favorable outcomes across additional sites and countries, Xeltis could strengthen its competitive position in innovative hemodialysis access solutions and potentially attract strategic interest or partnerships in the medtech space.